The FDA almost never pulls fully-approved drugs. Amylyx's ALS treatment might be the exception

Zachary Brennan

Senior Editor

Max Gelman

Senior Editor

Barring safety issues, the FDA almost never pulls fully-approved drugs from the market. But given the magnitude of the failure with Amylyx’s Phase III data …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

The FDA almost never pulls fully-approved drugs. Amylyx's ALS treatment might be the exception

Zachary Brennan

Senior Editor

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

The FDA al­most nev­er pulls ful­ly-ap­proved drugs. Amy­lyx's ALS treat­ment might be the ex­cep­tion

Senior Editor

Senior Editor

Sign up to read this article for free.

The FDA almost never pulls fully-approved drugs. Amylyx's ALS treatment might be the exception